Barclays analyst Matt Miksic maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $278.00. The

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area code 402-220-7223 for international calls. For today's call, all parties have been placed in a listen-only mode until the question-and-answer session.

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices,

In a report released yesterday, Josh Jennings from TD Cowen maintained a Hold rating on Becton Dickinson (BDX – Research Report), with a price

Becton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago. These figures are adjusted for non-recurring items.

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P's 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245

Reports Q1 revenue $5.2B, consensus $5.11B. “We delivered strong operational performance in Q1, with revenue growth, margin expansion and